Lyell Immunopharma appoints David Shook as CMO, Mark Meltz as general counsel

Lyell Immunopharma (LYEL) announced the appointment of David Shook as CMO and Mark Meltz as general counsel and corporate secretary. Prior to Lyell, Shook was CMO and head of research and development at Nkarta (NKTX) where he was responsible for leading the clinical development of multiple CAR NK cell product candidates for oncology. Prior to joining Lyell, Meltz was COO and general counsel of Kinnate Biopharma.